CRP and lobular neoplasia: More recently, a large longitudinal study from Europe identified the presence of anti-CRP antibodies at the onset of LN as a strong risk factor for a composite outcome of non-response, renal flare, and end-stage renal disease after 2 years of standard LN treatment [155].